Remote-Controlled Stem Cell Therapy
Revolutionising Regenerative Medicine
We developed a disruptive biotech nanotechnology which creates remote-controlled stem cells- technology which is at the cusp of beginning Phase 1 clinical trials after successful pre-clinical trials.
The technology answers the fundamental problem of selective stem cell differentiation. Stem cells in their current form are placed into a patient and are hoped to create the desired tissue purely based on their environment- which has a high failure rate. Through nanotechnology, we developed Remote-Controlled Stem Cell Technology, which allows clinicians to select the type of tissue they would like to create in situ. We are focussing first on spinal fusion, with future applications in the areas of oncology, neurodegenerative disease, arthritis, tendon repair, orthopaedics & spinal cord repair.
We are aiming to finally unlock the world of potential that stem cell therapies have been promising.
The technology has the potential to revolutionise the areas of regenerative medicine and stem cell therapies; and the underpinning facilitator of this technology has won the Nobel Prize in Chemistry in 2021!
We have recently concluded our successful pre-clinical trials and are gearing up to start Phase 1 human trials; paving the way to patients around the world. The initial therapy area we focus our attention on is Spinal Fusion- changing what is currently an invasive surgery into an outpatient injection procedure!
So how does the cell therapy work?
1) Nanoparticles with a magnetic core, coated with a biocompatible layer, are linked to one or more binding molecules.
2) The tagged nanoparticles bind to ion-channels or other molecular receptors on the cell membrane.
3) By subjecting the cells to a time-varying magnetic field, energy is transferred to the magnetic particles, which causes the specific receptor to be activated.
4)This leads to protein regulation and controlled cell responses.